Long-term outcomes in pulmonary arterial hypertension

被引：3

作者：

Thenappan, T. ^{[1
]}

Palevsky, H. I. ^{[2
]}

机构：

[1] Univ Chicago, Med Ctr, Dept Med, Cardiol Sect, Chicago, IL 60637 USA

[2] Univ Penn Hlth Syst, Penn Presbyterian Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA USA

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2009年 / 63卷

关键词：

INTRAVENOUS EPOPROSTENOL; SURVIVAL; THERAPY; REGISTRY; ANTICOAGULANT; METAANALYSIS; BOSENTAN; TRIALS;

D O I：

10.1111/j.1742-1241.2009.02128.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：42 / 44

页数：3

共 27 条

[1] Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines [J].

Badesch, David B. ;

Abman, Steven H. ;

Simonneau, Gerald ;

Rubin, Lewis J. ;

McLaughlin, Vallerie V. .

CHEST, 2007, 131 (06) :1917-1928

[2] Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil [J].

Barst, R. J. ;

Galie, N. ;

Naeije, R. ;

Simonneau, G. ;

Jeffs, R. ;

Arneson, C. ;

Rubin, L. J. .

EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) :1195-1203

[3] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[4] SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].

DALONZO, GE ;

BARST, RJ ;

AYRES, SM ;

BERGOFSKY, EH ;

BRUNDAGE, BH ;

DETRE, KM ;

FISHMAN, AP ;

GOLDRING, RM ;

GROVES, BM ;

KERNIS, JT ;

LEVY, PS ;

PIETRA, GG ;

REID, LM ;

REEVES, JT ;

RICH, S ;

VREIM, CE ;

WILLIAMS, GW ;

WU, M .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349

[5] Mechanisms of disease: Pulmonary arterial hypertension [J].

Farber, HW ;

Loscalzo, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (16) :1655-1665

[6]

Fischler M, 2008, SWISS MED WKLY, V138, P371, DOI 2008/25/smw-11914

[7] The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension [J].

Frank, H ;

Mlczoch, J ;

Huber, K ;

Schuster, E ;

Gurtner, HP ;

Kneussl, M .

CHEST, 1997, 112 (03) :714-721

[8] PRIMARY PULMONARY-HYPERTENSION - NATURAL-HISTORY AND THE IMPORTANCE OF THROMBOSIS [J].

FUSTER, V ;

STEELE, PM ;

EDWARDS, WD ;

GERSH, BJ ;

MCGOON, MD ;

FRYE, RL .

CIRCULATION, 1984, 70 (04) :580-587

[9] Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 [J].

Galie, Nazzareno ;

Olschewski, Horst ;

Oudiz, Ronald J. ;

Torres, Fernando ;

Frost, Adaani ;

Ghofrani, Hossein A. ;

Badesch, David B. ;

McGoon, Michael D. ;

McLaughlin, Vallerie V. ;

Roecker, Ellen B. ;

Gerber, Michael J. ;

Dufton, Christopher ;

Wiens, Brian L. ;

Rubin, Lewis J. .

CIRCULATION, 2008, 117 (23) :3010-3019

[10] A meta-analysis of randomized controlled trials in pulmonary arterial hypertension [J].

Galie, Nazzareno ;

Manes, Alessandra ;

Negro, Luca ;

Palazzini, Massimiliano ;

Bacchi-Reggiani, Maria Letizia ;

Branzi, Angelo .

EUROPEAN HEART JOURNAL, 2009, 30 (04) :394-403

← 1 2 3 →